CTOs on the Move

Avista Pharma

www.avistapharma.com

 
Avista Pharma Solutions is a contract development and manufacturing organization (CDMO) formed through the recent, strategic carve-outs of the CMC business of Array BioPharma, Inc. and contract services business of Scynexis, Inc. These two operations, along with the microbiology and analytical testing capabilities of the parent company Accuratus, create a combined business encompassing over 170,000 square feet of laboratory and manufacturing space which is capable of providing pharmaceutical clients with a broad suite of scientifically-differentiated services. These services are provided from a team with demonstrated expertise in process chemistry, analytical chemistry, manufacturing of novel drugs and specialized animal health services.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Linden Labs

Linden Labs is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galenea Corp

Galenea Corp is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mersana

Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.

XyloCor

XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001.

clarient

clarient is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.